Literature DB >> 6832294

The protective effect of polyriboinosinic acid-polyribocytidylic acid against the occurrence of galactosamine-induced liver cell injury in rat.

S Sakakibara, Y Shibayama, I Ueda, H Kagamiyama.   

Abstract

A marked increase of serum transaminase activities, histological changes of livers similar to those seen in viral hepatitis in man, and inhibition of hepatic protein synthesis were observed in rats following a single injection of D-galactosamine-HCl. These galactosamine-induced phenomena were prevented by the pretreatment of polyriboinosinic acid-polyribocytidylic acid 24 h before the galactosamine administration.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6832294     DOI： 10.1007/BF01958884

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  8 in total

1.  A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum.

Authors:  A KARMEN
Journal:  J Clin Invest       Date:  1955-01       Impact factor: 14.808

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 3.  Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death.

Authors:  K Decker; D Keppler
Journal:  Rev Physiol Biochem Pharmacol       Date:  1974       Impact factor: 5.545

4.  Inhibition of protein synthesis in rat liver by D-galactosamine.

Authors:  T Anukarahanonta; H Shinozuka; E Farber
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-03

5.  Experimental hepatitis induced by D-galactosamine.

Authors:  D Keppler; R Lesch; W Reutter; K Decker
Journal:  Exp Mol Pathol       Date:  1968-10       Impact factor: 3.362

6.  Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.

Authors:  A K Field; A A Tytell; G P Lampson; M R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

7.  Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.

Authors:  H B Greenberg; R B Pollard; L I Lutwick; P B Gregory; W S Robinson; T C Merigan
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

8.  Administration of human fibroblast interferon in chronic hepatitis-B infection.

Authors:  J Desmyter; J De Groote; V J Desmet; A Billiau; M B Ray; A F Bradburne; V G Edy; P De Somer
Journal:  Lancet       Date:  1976-09-25       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.